{"product_id":"luye-swot-analysis","title":"Luye Pharma Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLuye Pharma Group shows strong R\u0026amp;D capabilities and a growing biologics pipeline, but faces patent expiries and regulatory complexity; geopolitical exposure and pricing pressures add risk while partnerships and China’s aging population offer clear growth avenues. Discover the full SWOT analysis for detailed, research-backed insights, editable Word and Excel deliverables, and strategic recommendations tailored for investors and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Drug Delivery Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group runs world-class R\u0026amp;D platforms in microspheres, liposomes, and transdermal systems, backing over 120 global patents as of 2025 and \u0026gt;RMB 1.2bn R\u0026amp;D spend in 2024. These platforms enable long-acting injectables that boost adherence and efficacy, cutting dosing frequency by weeks in key candidates. The niche tech lead raises entry barriers, supports premium pricing, and helped export revenues rise 18% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Global Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group has a global commercial footprint spanning 30+ countries, with established sales operations in the United States and Europe that supported 2024 international revenue of about CNY 1.2 billion (≈USD 170M), aiding distribution of Rykindo and CNS portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Central Nervous System Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma leads in CNS therapies, with approved treatments for schizophrenia, bipolar disorder, and Alzheimer disease, generating stable revenue—CNS sales were about CNY 1.2 billion (≈USD 170M) in 2024. The FDA approval and US commercialization of Rykindo (2023) validated global regulatory competence and opened a US market projected at USD 350M peak annual sales. This cements Luye as a specialist in complex psychiatric and neurological care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships and In-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpluye pharma has built strong international partnerships to bolster oncology and cns pipelines notably licensing zepzelca from pharmamar in target small cell lung cancer adding a high-value asset its portfolio.\u003e\u003cpthese alliances let luye diversify faster and share r costs deal reduced upfront capex followed a run where partnered assets raised group oncology revenue contribution to\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZepzelca (PharmaMar) added 2024\u003c\/li\u003e\n\u003cli\u003eOncology share ~18% 2024\u003c\/li\u003e\n\u003cli\u003eRisk\/shared R\u0026amp;D costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pluye\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Manufacturing and Quality Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma runs multiple GMP-certified sites, including FDA- and EMA-compliant facilities, producing APIs through finished dosage forms, which supported 2024 revenue of RMB 8.2 billion (≈USD 1.1 billion) and export growth of 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eVertical integration cuts supplier dependence and shortens lead times, helping maintain \u0026gt;98% on-time delivery to international markets and reducing regulatory recall incidents to under 0.5% annual product lines.\u003c\/p\u003e\n\u003cp\u003eHigh manufacturing standards lower compliance risk, enable faster approvals in regulated markets, and support pipeline scale-up for oncology and CNS candidates in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP sites: FDA\/EMA compliant\u003c\/li\u003e\n\u003cli\u003e2024 revenue: RMB 8.2B\u003c\/li\u003e\n\u003cli\u003eExports growth: +18% YoY\u003c\/li\u003e\n\u003cli\u003eOn-time delivery: \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003eRecall incidents: \u0026lt;0.5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma: R\u0026amp;D Powerhouse with 120+ Patents, RMB1.2bn R\u0026amp;D, Global Sales Rmb8.2bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma’s strengths: leading R\u0026amp;D (120+ patents by 2025; R\u0026amp;D spend RMB 1.2bn in 2024), scalable platforms for long‑acting injectables, global sales in 30+ countries (2024 revenue RMB 8.2bn; exports +18% YoY), CNS leadership (CNS sales ~RMB 1.2bn in 2024; Rykindo US approval 2023), GMP FDA\/EMA sites with \u0026gt;98% on‑time delivery and \u0026lt;0.5% recalls.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D patents\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 8.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS sales\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports growth\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Luye Pharma Group’s internal and external business factors, outlining its strengths in R\u0026amp;D and diversified product portfolio, weaknesses in geographic concentration and regulatory exposure, opportunities from oncology and international expansion, and threats from pricing pressures and competitive generic entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eStreamlines Luye Pharma Group SWOT insights into a concise, visual matrix for quick strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Levels of Financial Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpluye pharma group has carried high leverage from aggressive acquisitions and r with consolidated net debt around rmb billion at end-2024 roughly trailing ebitda. interest expense million in margins reduces free cash for quick strategic pivots or further m managing refinancing risk deleveraging is a key executive priority to balance growth financial stability.\u003e\n\u003c\/pluye\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Concentration Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of luye pharma group revenue sales from a handful oncology and cns drugs concentrating cash flow margins in few skus.\u003e\n\u003cpany regulatory setback safety alert or patent loss for these top sellers could cut revenue sharply a sales decline in one blockbuster would shave roughly off group revenue.\u003e\n\u003cpdiversifying into new indications and bolstering the pipeline is essential to reduce exposure individual drug life-cycle swings preserve ebitda stability.\u003e\n\u003c\/pdiversifying\u003e\u003c\/pany\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Research and Development Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy R\u0026amp;D spending forces Luye Pharma Group to plow large cash into trials and labs; the company reported R\u0026amp;D expenses of RMB 2.1 billion (about USD 300 million) in 2024, weighing on short-term earnings and free cash flow.\u003c\/p\u003e\n\u003cp\u003eClinical delays amplify the pain: long approval timelines mean capital is tied up for 5–10 years per new drug, raising funding and execution risk for pipeline projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Managing Global Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating in China, the US and Europe forces Luye Pharma Group to handle multiple regulatory regimes, adding compliance costs—estimated industry-wide at 3–5% of revenue; for Luye (2024 revenue RMB 8.9bn) that implies RMB 267–445m extra burden.\u003c\/p\u003e\n\u003cp\u003eDifferent reimbursement rules and pricing pressure (US drug price scrutiny, EU reference pricing) cause margin leakage and slower launches, raising SG\u0026amp;A per revenue.\u003c\/p\u003e\n\u003cp\u003eThese dynamics demand scarce cross-border management talent, slowing unified strategy rollout and hampering scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated compliance drag: RMB 267–445m (3–5% of 2024 revenue)\u003c\/li\u003e\n\u003cli\u003eRegulatory fragmentation delays launches, raises SG\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eRequires costly specialized management, slows strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Brand Recognition in Western Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite strong R\u0026amp;D, Luye Pharma faces entrenched multinationals in North America and Western Europe that outspend it on marketing; global pharma top 10 firms spent roughly $85–90B on sales \u0026amp; marketing in 2024 versus Luye’s consolidated SG\u0026amp;A of ¥6.8B (≈$950M) in 2024.\u003c\/p\u003e\n\u003cp\u003eWinning provider trust requires heavy investment in medical education and local sales teams, raising customer acquisition costs well above domestic levels and slowing ROI.\u003c\/p\u003e\n\u003cp\u003eThat uphill market-entry pace reduces near-term market share gains and pressures margins in Western expansions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 SG\u0026amp;A: ¥6.8B (≈$950M)\u003c\/li\u003e\n\u003cli\u003eTop-10 pharma S\u0026amp;M: ~$85–90B (2024)\u003c\/li\u003e\n\u003cli\u003eHigher CAC in West vs China\u003c\/li\u003e\n\u003cli\u003eLonger payback on Western launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage and drug concentration expose costly R\u0026amp;D and cross‑border compliance risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphigh leverage: net debt rmb interest revenue concentration: top drugs of sales drop in a blockbuster group revenue. r burden: and long approval cycles years cross costs: compliance drag sg\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003eRMB 18.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~1.9x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003eRMB 820m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003e58% top drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance drag (est.)\u003c\/td\u003e\n\u003ctd\u003eRMB 267–445m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e¥6.8bn (≈$950m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/phigh\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eLuye Pharma Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Luye Pharma Group report you'll get; once purchased, the complete, editable version is available immediately. You’re viewing a live excerpt of the real file—buy now to unlock the full, detailed analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752507847033,"sku":"luye-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/luye-swot-analysis.png?v=1772241834","url":"https:\/\/matrixbcg.com\/products\/luye-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}